Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manige Konig

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Lancet (London, England)|June 27, 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyJuan P Frias, Stanley Hsia, Sarah Eyde, et al.
Cardiovascular Diabetology|September 26, 2021
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWINDManige Konig, Matthew C Riddle, Helen M Colhoun, et al.
The New England Journal of Medicine|June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesitySean Wharton, Thomas Blevins, Lisa Connery, et al.
Journal of Lipid Research|January 25, 2013
Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunctionHong Wang, Urmila Sreenivasan, Da-Wei Gong, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 13, 2025
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy AdultsTsuyoshi Fukuda, Brian R Thompson, Bram Brouwers, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2021
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialMatthew C Riddle, Hertzel C Gerstein, Denis Xavier, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Lancet (London, England)|June 27, 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyJuan P Frias, Stanley Hsia, Sarah Eyde, et al.
Cardiovascular Diabetology|September 26, 2021
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWINDManige Konig, Matthew C Riddle, Helen M Colhoun, et al.
The New England Journal of Medicine|June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesitySean Wharton, Thomas Blevins, Lisa Connery, et al.
Journal of Lipid Research|January 25, 2013
Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunctionHong Wang, Urmila Sreenivasan, Da-Wei Gong, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 13, 2025
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy AdultsTsuyoshi Fukuda, Brian R Thompson, Bram Brouwers, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2021
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialMatthew C Riddle, Hertzel C Gerstein, Denis Xavier, et al.
Pageof 3